As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.
How we can help
Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:
- A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
- The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
- Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
- Country-specific treatment algorithms and reimbursement scenarios
- Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
- Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team
